Basit öğe kaydını göster

dc.contributor.authorConer, Ali
dc.contributor.authorAydinalp, Alp
dc.contributor.authorMuderrisoglu, Haldun
dc.date.accessioned2021-08-17T12:21:41Z
dc.date.available2021-08-17T12:21:41Z
dc.date.issued2020
dc.identifier.issn1871-5303en_US
dc.identifier.urihttp://hdl.handle.net/11727/6280
dc.description.abstractObjective: Risk stratification and prompt treatment are essential for the management of acute coronary syndromes (ACS) and prediction of future prognosis. Subclinical vascular inflammation and novel biomarkers play an important role in the clinical evaluation of ACS patients. Methods: We enrolled patients who were admitted to emergency service with unstable angina or non-ST segment elevated ACS (NSTE-ACS) in the study population. Coronary artery disease (CAD) complexity was determined via evaluation of angiographical views and peripheral venous blood samples were collected to measure highly sensitive C-reactive protein (hs-CRP) and soluble form of Lectin-like OxLDL receptor-1 (sLOX-1) levels. Results: A total of 40 patients were enrolled in the study population, mean age was 65.1 +/- 13.8 years and male gender percentage was 52.5%. Twenty-nine of patients had NSTE-ACS and 11 patients had unstable angina presentation. The modified Gensini scores were higher for patients with elevated hs-CRP and sLOX-1 levels. Conclusion: Vascular inflammation displays the onset of ACS and it is related to more complex CAD in these patients. An increase in sLOX-1 expression is closely related to anatomical complexity of CAD in ACS.en_US
dc.language.isoengen_US
dc.relation.isversionof10.2174/1871530319666190408145905en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectVascular inflammationen_US
dc.subjectatherosclerotic plaque burdenen_US
dc.subjectacute coronary syndromesen_US
dc.subjectrisk stratificationen_US
dc.subjecths-CRPen_US
dc.subjectLectin-like OxLDL receptor-1en_US
dc.titleEvaluation of hs-CRP and sLOX-1 Levels in Moderate-to-High Risk Acute Coronary Syndromesen_US
dc.typearticleen_US
dc.relation.journalENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETSen_US
dc.identifier.volume20en_US
dc.identifier.issue1en_US
dc.identifier.startpage96en_US
dc.identifier.endpage103en_US
dc.identifier.wos000506004000010en_US
dc.identifier.scopus2-s2.0-85077948575en_US
dc.contributor.pubmedID30961517en_US
dc.contributor.orcID0000-0002-9635-6313en_US
dc.contributor.orcID0000-0002-3761-8782en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAG-8233-2020en_US
dc.contributor.researcherIDAAD-5841-2021en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster